Biotechnology Ultrasector Profund Fund Net Income
| BIPIX Fund | USD 71.95 0.14 0.19% |
As of the 27th of January, Biotechnology Ultrasector shows the Mean Deviation of 1.8, risk adjusted performance of 0.1367, and Downside Deviation of 2.28. Biotechnology Ultrasector technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.
Biotechnology Ultrasector's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biotechnology Ultrasector's valuation are provided below:Biotechnology Ultrasector Profund does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Biotechnology |
Biotechnology Ultrasector 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biotechnology Ultrasector's mutual fund what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biotechnology Ultrasector.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Biotechnology Ultrasector on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Biotechnology Ultrasector Profund or generate 0.0% return on investment in Biotechnology Ultrasector over 90 days. Biotechnology Ultrasector is related to or competes with Internet Ultrasector, Columbia Adaptive, Biotechnology Ultrasector, Royce Small-cap, Ashmore Emerging, Ashmore Emerging, and Neuberger Berman. The index is designed to measure the performance of biotechnology companies included in the SP Total Market Index More
Biotechnology Ultrasector Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biotechnology Ultrasector's mutual fund current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biotechnology Ultrasector Profund upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.28 | |||
| Information Ratio | 0.1426 | |||
| Maximum Drawdown | 10.98 | |||
| Value At Risk | (3.27) | |||
| Potential Upside | 4.29 |
Biotechnology Ultrasector Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotechnology Ultrasector's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biotechnology Ultrasector's standard deviation. In reality, there are many statistical measures that can use Biotechnology Ultrasector historical prices to predict the future Biotechnology Ultrasector's volatility.| Risk Adjusted Performance | 0.1367 | |||
| Jensen Alpha | 0.3326 | |||
| Total Risk Alpha | 0.1825 | |||
| Sortino Ratio | 0.1458 | |||
| Treynor Ratio | 0.4004 |
Biotechnology Ultrasector January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1367 | |||
| Market Risk Adjusted Performance | 0.4104 | |||
| Mean Deviation | 1.8 | |||
| Semi Deviation | 1.82 | |||
| Downside Deviation | 2.28 | |||
| Coefficient Of Variation | 566.68 | |||
| Standard Deviation | 2.34 | |||
| Variance | 5.45 | |||
| Information Ratio | 0.1426 | |||
| Jensen Alpha | 0.3326 | |||
| Total Risk Alpha | 0.1825 | |||
| Sortino Ratio | 0.1458 | |||
| Treynor Ratio | 0.4004 | |||
| Maximum Drawdown | 10.98 | |||
| Value At Risk | (3.27) | |||
| Potential Upside | 4.29 | |||
| Downside Variance | 5.21 | |||
| Semi Variance | 3.31 | |||
| Expected Short fall | (1.98) | |||
| Skewness | (0.01) | |||
| Kurtosis | (0.04) |
Biotechnology Ultrasector Backtested Returns
Biotechnology Ultrasector appears to be very steady, given 3 months investment horizon. Biotechnology Ultrasector secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the fund had a 0.15 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Biotechnology Ultrasector Profund, which you can use to evaluate the volatility of the entity. Please makes use of Biotechnology Ultrasector's Risk Adjusted Performance of 0.1367, downside deviation of 2.28, and Mean Deviation of 1.8 to double-check if our risk estimates are consistent with your expectations. The fund shows a Beta (market volatility) of 1.0, which signifies a somewhat significant risk relative to the market. Biotechnology Ultrasector returns are very sensitive to returns on the market. As the market goes up or down, Biotechnology Ultrasector is expected to follow.
Auto-correlation | 0.52 |
Modest predictability
Biotechnology Ultrasector Profund has modest predictability. Overlapping area represents the amount of predictability between Biotechnology Ultrasector time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biotechnology Ultrasector price movement. The serial correlation of 0.52 indicates that about 52.0% of current Biotechnology Ultrasector price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 4.84 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Biotechnology Ultrasector Profund reported net income of 0.0. This indicator is about the same for the ProFunds average (which is currently at 0.0) family and about the same as Trading--Leveraged Equity (which currently averages 0.0) category. This indicator is about the same for all United States funds average (which is currently at 0.0).
Biotechnology Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Ultrasector's current stock value. Our valuation model uses many indicators to compare Biotechnology Ultrasector value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Ultrasector competition to find correlations between indicators driving Biotechnology Ultrasector's intrinsic value. More Info.Biotechnology Ultrasector Profund is the top fund in price to earning among similar funds. It also is the top fund in price to book among similar funds fabricating about 2.19 of Price To Book per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotechnology Ultrasector's earnings, one of the primary drivers of an investment's value.Fund Asset Allocation for Biotechnology Ultrasector
The fund consists of 75.46% investments in stocks, with the rest of investments allocated between different money market instruments.Asset allocation divides Biotechnology Ultrasector's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Biotechnology Fundamentals
| Price To Earning | 2.37 X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 4.56 X | ||||
| Total Asset | 175.48 M | ||||
| Annual Yield | 0 % | ||||
| Year To Date Return | 7.37 % | ||||
| One Year Return | 58.35 % | ||||
| Three Year Return | 17.84 % | ||||
| Five Year Return | 9.62 % | ||||
| Ten Year Return | 24.20 % | ||||
| Net Asset | 178.6 M | ||||
| Minimum Initial Investment | 15 K | ||||
| Cash Position Weight | 24.54 % | ||||
| Equity Positions Weight | 75.46 % |
About Biotechnology Ultrasector Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Ultrasector Profund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Ultrasector Profund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Ultrasector financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Ultrasector security.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |